Dexamethasone
Brand names: Dexamethasone, Martapan
Dexamethasone is a potent long-acting glucocorticoid used in neurology principally to reduce vasogenic cerebral oedema associated with brain tumours and certain intracranial pathology, and as adjunctive therapy in bacterial meningitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It binds glucocorticoid receptors to exert powerful anti-inflammatory and immunosuppressive effects and stabilises the blood-brain barrier, reducing peritumoural oedema; it has negligible mineralocorticoid activity.
Prescribing in practice
- Do not stop abruptly after more than a short course, as adrenal suppression risks an adrenal crisis; dosing should be tapered and a steroid emergency card issued.
- Co-prescribe gastroprotection where indicated and monitor for hyperglycaemia, neuropsychiatric effects and increased infection risk during treatment.
- Give doses earlier in the day to limit insomnia and counsel on raised blood glucose, mood changes and proximal myopathy with prolonged use.
Monitoring
Monitor blood glucose, blood pressure, weight, mood and signs of infection during treatment, with bone and gastrointestinal protection considered for prolonged courses.
Counselling the patient
- Never stop the steroid suddenly and carry a steroid alert card.
- Report mood changes, marked thirst, infection symptoms or indigestion.
- Take in the morning to reduce difficulty sleeping.
Evidence & guidelines
Adjunctive dexamethasone improves outcomes in bacterial meningitis in appropriate patients, and it is a long-standing standard treatment for symptomatic cerebral oedema from intracranial tumours.
Reference: NICE NG240 Bacterial Meningitis; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS